Clinical Trials in Los Angeles

Showing 5341-5360 of 16,901 trials

Oral ONC201 in Adult Recurrent Glioblastoma

NCT02525692

This was a Phase 2, open-label, 6-arm, multi-center study of dordaviprone (ONC201) in patients with recurrent glioblastoma (Arms A, B, and C), H3 K27M-mutant diffuse glioma (Arm D), or diffuse midline glioma (Arms E and F). The primary objective of this study was the assessment of dordaivprone (ONC201) anti-tumor activity through progression-free survival at 6 months using Response Assessment in Neuro-Oncology (RANO) criteria for high-grade glioma (HGG).

GlioblastomaDiffuse Midline GliomaH3 K27M Glioma+3 more

Jazz Pharmaceuticals84 participantsStarted Jan 2016

Los Angeles, California, United States • Miami, Florida, United States • Boston, Massachusetts, United States +2 more locations

Active Not RecruitingPhase 2< 1 mile

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

NCT03634540

This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily.

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Carcinoma (ccRCC)Kidney Cancer+6 more

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)118 participantsStarted Sep 2018

Los Angeles, California, United States • Los Angeles, California, United States • Miami, Florida, United States +7 more locations

Oral ONC201 in Adult Recurrent Glioblastoma

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Find Trials by Condition in Los Angeles

Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients

CYPRESS Efficacy and Safety Study Extension

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

A Safety and Efficacy Study to Evaluate AIV001 in Wound Healing Following Surgical Incision

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer